| 000 | 01535 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250512073700.0 | ||
| 264 | 0 | _c19860429 | |
| 008 | 198604s 0 0 fre d | ||
| 022 | _a0003-3898 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRoncato, M | |
| 245 | 0 | 0 |
_a[Biological profile of the 1st 4 hours of a thrombolytic treatment combining urokinase with lysyl-plasminogen]. _h[electronic resource] |
| 260 |
_bAnnales de biologie clinique _c1985 |
||
| 300 |
_a851-5 p. _bdigital |
||
| 500 | _aPublication Type: English Abstract; Journal Article | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aArterial Occlusive Diseases _xblood |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFibrin Fibrinogen Degradation Products |
| 650 | 0 | 4 | _aFibrinogen |
| 650 | 0 | 4 |
_aFibrinolysis _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intra-Arterial |
| 650 | 0 | 4 |
_aLeg _xblood supply |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeptide Fragments _xadministration & dosage |
| 650 | 0 | 4 |
_aPlasminogen _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aUrokinase-Type Plasminogen Activator _xadministration & dosage |
| 650 | 0 | 4 | _aalpha-2-Antiplasmin |
| 700 | 1 | _aVitoux, J F | |
| 700 | 1 | _aPernes, J M | |
| 700 | 1 | _aAiach, M | |
| 700 | 1 | _aFiessinger, J N | |
| 700 | 1 | _aGaux, J C | |
| 700 | 1 | _aHousset, E | |
| 700 | 1 | _aLeclerc, M | |
| 773 | 0 |
_tAnnales de biologie clinique _gvol. 43 _gno. 6 _gp. 851-5 |
|
| 999 |
_c3838670 _d3838670 |
||